CN101497640B - 一种氯法拉滨的晶型 - Google Patents
一种氯法拉滨的晶型 Download PDFInfo
- Publication number
- CN101497640B CN101497640B CN2008100086670A CN200810008667A CN101497640B CN 101497640 B CN101497640 B CN 101497640B CN 2008100086670 A CN2008100086670 A CN 2008100086670A CN 200810008667 A CN200810008667 A CN 200810008667A CN 101497640 B CN101497640 B CN 101497640B
- Authority
- CN
- China
- Prior art keywords
- clofarex
- crystal formation
- crystal
- clofarabine
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 84
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 title claims abstract description 71
- 229960000928 clofarabine Drugs 0.000 title claims abstract description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 56
- 238000001035 drying Methods 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000001953 recrystallisation Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 7
- 238000001228 spectrum Methods 0.000 abstract description 6
- 239000004698 Polyethylene Substances 0.000 abstract description 2
- -1 polyethylene Polymers 0.000 abstract description 2
- 229920000573 polyethylene Polymers 0.000 abstract description 2
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 229920003023 plastic Polymers 0.000 abstract 1
- 239000004033 plastic Substances 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000000843 powder Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 12
- 230000008025 crystallization Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- HBJGQJWNMZDFKL-UHFFFAOYSA-N 2-chloro-7h-purin-6-amine Chemical compound NC1=NC(Cl)=NC2=C1NC=N2 HBJGQJWNMZDFKL-UHFFFAOYSA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910002483 Cu Ka Inorganic materials 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920001617 Vinyon Polymers 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100029010 D-aminoacyl-tRNA deacylase 1 Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 101000838688 Homo sapiens D-aminoacyl-tRNA deacylase 1 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- NUMSNYICEAINNJ-HJCWDVFASA-N [(2R,3R,4R,5S)-5-acetyloxy-3,4-dibenzoyl-3,4-dihydroxyoxolan-2-yl]methyl benzoate Chemical compound C(C)(=O)O[C@H]1[C@](O)([C@](O)([C@H](O1)COC(C1=CC=CC=C1)=O)C(C1=CC=CC=C1)=O)C(C1=CC=CC=C1)=O NUMSNYICEAINNJ-HJCWDVFASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Abstract
Description
实验项目 | 时间 天 | 性状 | 吸湿增重 (%) | 干燥失重 (%) | 有关物质 (%) | 含量(%) |
强光照射 | 0 5 10 | 白色结晶性粉末白色结晶性粉末白色结晶性粉末 | --- | 0.13 0.12 0.13 | 0.14 0.19 0.17 | 99.6 99.6 99.8 |
高温实验 | 0 5 10 | 白色结晶性粉末白色结晶性粉末白色结晶性粉末 | --- | 0.13 0.02 0.01 | 0.14 0.20 0.19 | 99.6 99.4 99.6 |
高湿实验 | 0 5 10 | 白色结晶性粉末白色结晶性粉末白色结晶性粉末 | -2.83.6 | 0.13 2.79 3.75 | 0.14 0.19 0.16 | 99.6 99.5 99.8 |
实验项目 | 时间 月 | 性状 | 干燥失重 (%) | 有关物质 (%) | 含量 (%) |
加速实验 | 0 1 2 3 6 | 白色结晶性粉末 白色结晶性粉末 白色结晶性粉末 白色结晶性粉末 白色结晶性粉末 | 0.13 0.13 0.14 0.11 0.12 | 0.14 0.19 0.19 0.16 0.18 | 99.6 99.7 99.8 99.8 99.7 |
长期实验 | 0 3 6 | 白色结晶性粉末 白色结晶性粉末 白色结晶性粉末 | 0.13 0.11 0.12 | 0.14 0.19 0.19 | 99.6 99.5 99.7 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100086670A CN101497640B (zh) | 2008-01-30 | 2008-01-30 | 一种氯法拉滨的晶型 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100086670A CN101497640B (zh) | 2008-01-30 | 2008-01-30 | 一种氯法拉滨的晶型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101497640A CN101497640A (zh) | 2009-08-05 |
CN101497640B true CN101497640B (zh) | 2011-09-14 |
Family
ID=40944927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100086670A Expired - Fee Related CN101497640B (zh) | 2008-01-30 | 2008-01-30 | 一种氯法拉滨的晶型 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101497640B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109320567A (zh) * | 2018-11-17 | 2019-02-12 | 扬州工业职业技术学院 | 一种绿色合成氯法拉滨医药中间体的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5384310A (en) * | 1989-05-23 | 1995-01-24 | Southern Research Institute | 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions |
EP1261350B1 (en) * | 2000-02-18 | 2006-07-12 | Southern Research Institute | Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-9h-purin-6-amine |
-
2008
- 2008-01-30 CN CN2008100086670A patent/CN101497640B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5384310A (en) * | 1989-05-23 | 1995-01-24 | Southern Research Institute | 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions |
EP1261350B1 (en) * | 2000-02-18 | 2006-07-12 | Southern Research Institute | Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-9h-purin-6-amine |
Also Published As
Publication number | Publication date |
---|---|
CN101497640A (zh) | 2009-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107266348B (zh) | 联苯乙酮腙-3-吲哚甲醛西弗碱的制备、结构和用途 | |
CN110092775A (zh) | 靶向cdk4/6激酶抑制剂的晶型 | |
CN111484435B (zh) | 四氢吡咯烷类化合物或其药学上可接受的盐及其制备方法和应用 | |
EP3159349A1 (en) | Lobaplatin crystal, preparation method and pharmaceutical application | |
CN103739616A (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
US9085607B2 (en) | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof | |
CN107043345B (zh) | 联苯乙酮腙-吲哚啉-2,3-二酮西弗碱的制备、结构和用途 | |
CN101497640B (zh) | 一种氯法拉滨的晶型 | |
US20170051002A1 (en) | Rebaudioside A Crystal And Its Preparation Method And Use | |
CN106432269A (zh) | 一种采用高通量药物晶型快速筛选技术制备的头孢拉定化合物及其制剂 | |
CN105440082B (zh) | 一种洛铂晶体、制备方法及药物应用 | |
CN107266349B (zh) | 联苯乙酮腙-2-吲哚甲醛西弗碱的制备、结构和用途 | |
CN105198932A (zh) | 洛铂二水合物、制备方法及药物应用 | |
EP3943498A1 (en) | Brd4 inhibitor compound in solid form and preparation method therefor and application thereof | |
CN105440083B (zh) | 一种洛铂晶体、制备方法及药物应用 | |
CN105218587B (zh) | 一种洛铂晶体、制备方法及药物应用 | |
CN105330702B (zh) | 一种洛铂晶体、制备方法及药物应用 | |
CN107118147B (zh) | 联苯乙酮腙-3-乙酰基吲哚西弗碱的制备、结构和用途 | |
CN105859748B (zh) | 多环化合物钠盐及其多晶型、制备方法及应用 | |
CN105198933A (zh) | 一种洛铂晶体、制备方法及药物应用 | |
CN107043344B (zh) | 联苯乙酮腙-n-甲基-3-吲哚甲醛西弗碱的制备、结构和用途 | |
CN104610356A (zh) | 一种稳定的磷酸酯结晶物及其制备方法 | |
WO2022067724A1 (zh) | 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用 | |
CN114746426B (zh) | 作为acc1和acc2抑制剂的晶型及其制备方法和应用 | |
CN108658945A (zh) | 一种微管蛋白抑制剂(vda-1)的a晶型 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: JIANGSU CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 |